Results 61 to 70 of about 43,363 (192)

Luteinizing hormone receptor knockout mouse: What has it taught us?

open access: yesAndrology, EarlyView.
Abstract Luteinizing hormone (LH), along with its agonist choriongonadotropin (hCG) in humans, is the key hormone responsible for the tropic regulation of the gonadal function. LH and hCG act through their cognate receptor, the luteinizing hormone/choriongonadotropin receptor (LHCGR; more appropriately LHR in rodents lacking CG), located in the testis ...
Ilpo T. Huhtaniemi
wiley   +1 more source

Assessment of established techniques to determine developmental and malignant potential of human pluripotent stem cells

open access: yesNature Communications, 2018
The International Stem Cell Initiative tests methods in a multisite study to detect pluripotency and teratoma formation (PluriTest, Embryoid Body and Teratoma methods) in human pluripotent stem cells.
The International Stem Cell Initiative
doaj   +1 more source

Cervico mediastinal teratoma in adult: A very rare presentation

open access: yesLung India, 2015
Teratoma is a rare presentation in adult, specifically in cervico-mediastinal region. We reported two adult patients with diagnosis of cervico-mediastinal teratoma and operated them.
Ali Sadrizadeh   +2 more
doaj   +1 more source

Prenatal Exophthalmia Revealing a Postnatal Orbital Teratoma

open access: yesCase Reports in Ophthalmological Medicine, 2020
Purpose. Teratomas are congenital tumors of stem cells derived from the three germ layers. They are frequently located in the sacrococcygeal region. Orbital teratoma is rare with less than 70 cases reported until 2016.
Ahgbatouhabeba Ahnoux-Zabsonre   +5 more
doaj   +1 more source

Malignancy within a tail gut cyst:a case of retrorectal carcinoid tumour [PDF]

open access: yes, 2014
Purpose. Tailgut cysts with malignant transformation are rare entities. We discuss the diagnostic strategy and treatment of a malignancy within a tailgut cyst. Methods.
Abukar, A. A.   +7 more
core   +7 more sources

BRD9 inhibition as potential treatment option for testicular germ cell tumors

open access: yesAndrology, EarlyView.
Abstract Background Testicular germ cell tumors (TGCT) are the predominant tumor in younger males. Usually, 5‐year survival rates are quite high, but 15–20% of patients with metastatic non‐seminomas are resistant to standard cisplatin‐based therapy.
Aylin Hansen   +5 more
wiley   +1 more source

Adult-onset spinal teratoma: a case report and review

open access: yesNeurologijos seminarai, 2019
Teratoma is defined as a neoplasm that is composed of a variety of parenchymal cell types derived from three germinal layers (endoderm, mesoderm and ectoderm).
K. Blank   +3 more
doaj   +1 more source

An ex vivo gene therapy approach to treat muscular dystrophy using inducible pluripotent stem cells. [PDF]

open access: yes, 2013
Duchenne muscular dystrophy is a progressive and incurable neuromuscular disease caused by genetic and biochemical defects of the dystrophin-glycoprotein complex.
Borges, Luciene   +11 more
core   +2 more sources

Semen quality in patients with testicular cancer is associated with age and with greatly elevated levels of beta human chorionic gonadotropin

open access: yesAndrology, EarlyView.
Abstract Background Poor semen quality is a well‐known feature in patients with testicular germ cell tumours (GCTs) at the time of diagnosis but the underlying biological reasons are incompletely understood. Objectives This study aimed to identify GCT‐specific clinical factors that are involved with poor semen quality in GCT patients.
Klaus‐Peter Dieckmann   +9 more
wiley   +1 more source

Inhibition of HMGA2 Leads to Reduced Cell Proliferation and Increased Apoptosis in Human Embryonal Carcinoma Cell Lines

open access: yesAndrology, EarlyView.
ABSTRACT Background The most prevalent solid tumors in young men are testicular germ cell tumors (TGCTs), and embryonal carcinoma is the most common subtype among non‐seminomatous germ cell tumors (NSGCTs). Despite the excellent cure rates of cisplatin‐based chemotherapy, resistance develops in 15%–30% of patients with metastatic cancer, which results ...
Marco De Martino   +5 more
wiley   +1 more source

Home - About - Disclaimer - Privacy